Monarch Capital Management Inc. Sells 2,094 Shares of Pfizer Inc. (NYSE:PFE)

Monarch Capital Management Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 1.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 106,132 shares of the biopharmaceutical company’s stock after selling 2,094 shares during the quarter. Monarch Capital Management Inc.’s holdings in Pfizer were worth $2,970,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of PFE. Clifford Swan Investment Counsel LLC raised its stake in Pfizer by 4.7% in the fourth quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after buying an additional 18,611 shares during the last quarter. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in Pfizer in the 4th quarter worth approximately $16,166,000. First Heartland Consultants Inc. grew its position in Pfizer by 43.3% during the 4th quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 3,933 shares during the last quarter. ORG Partners LLC increased its stake in Pfizer by 1,729.9% during the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 44,458 shares in the last quarter. Finally, Kempner Capital Management Inc. acquired a new position in Pfizer during the 1st quarter valued at approximately $2,439,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE traded up $0.12 during trading on Friday, reaching $28.90. 21,885,329 shares of the company’s stock traded hands, compared to its average volume of 39,008,852. The firm has a market cap of $163.76 billion, a PE ratio of -481.67, a P/E/G ratio of 0.98 and a beta of 0.69. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $36.94. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The company has a 50-day simple moving average of $28.85 and a 200-day simple moving average of $27.96.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.67 EPS. As a group, analysts predict that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.81%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is -2,800.00%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Morgan Stanley boosted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.